Introduction: Ketamine associated cystitis was first reported in 2007. Although many articles have been published concerning the effects of ketamine on lower urinary tract, not much focus had been put on the Quality of Life (QoL). This study was to assess lower urinary tract symptoms (LUTS) and QoL in ketamine abusers. Methods: One hundred ketamine abusers with LUTS were included in the study. All patients were interviewed by one of the three trained investigators through face-to-face interview. Their LUTS were evaluated by the survey instrument consisting of International Prostate Symptom Score (IPSS) and 7-points Likert-type QoL scale. Results: Sixty-six of them had moderate symptoms and 16 suffered from heavy symptoms. Eighty-one percent patients reported storage symptoms compared to 41% with voiding symptoms. Mono-ketamine abusers (MKA) had higher scores in IPSS, QoL, storage and voiding symptoms than polydrug abusers (PDA). Multiple linear regression analysis demonstrated that lower educational background, MKA, and longer duration of ketamine abuse were found to be predicting factors on IPSS and QoL. Conclusions: LUTS in ketamine abusers are mostly moderate to severe, and their quality of life were wrecked. Mono-ketamine abusers have more severe LUTS and lower quality of life than poly-drug users. Lower educational level, mono-ketamine abuser and longer duration of abuse are independent predictors of severity of LUTS and QoL. (Hong Kong j.emerg
Introduction
Ketamine associated cystitis was first reported in 2007, 1, 2 which is characterised by lower urinary tract symptoms (LUTS) including dysuria, painful haematuria, urinary urgency, urge incontinence, frequency and nocturia, with or without upper urinary tract involvement. With the exclusion of other urinary tract diseases such as urinary tract infections, tuberculosis and urinary tumours, LUTS can also be seen in long-term ketamine abusers. 2, 3 Cessation of ketamine abuse and early treatment of the damaging effects on patients may result in good outcomes. 3, 4 Ketamine toxicity in urinary tract was first addressed as ketamine-associated bladder dysfunction 1 and ketamine-associated ulcerative cystitis, 2 partly due to apparent LUTS and lesions manifested as decreased bladder volume and fibrosed bladder wall. In fact, about half of these patients also have upper urinary tract involved. [2] [3] [4] [5] It may be more appropriate to use the term "ketamine-induced uropathy" for this clinical entity. 6, 7 It was not uncommon that the ketamine abusers are in fact abusing poly-drugs. In a study by Winstock et al in 2010, most ketamine abusers were poly-drug abusers including 3,4-methylenedioxymethamphetamine, cannabis, cocaine, tobacco, mephedrone, amphetamine and isopropyl nitrate. 8 Despite LUTS in ketamine abusers had been hot topic in research in recent years, not much focus had been put on the quality of life among ketamine abusers, their predictors and the association with LUTS. This study aims to report the International Prostate Symptom Score (IPSS) and Quality of Life (QoL) among ketamine abusers. In addition, predicting factors of urinary symptom severity and QoL were explored.
Methods

Study setting and participants
From March 2013 to May 2014, 100 patients were recruited from two hospitals (Brain Hospital of Hunan Province and Second Xiangya Hospital, Central South University) and Hunan Kangda Detoxification Center. Among them, 62 were hospitalised in the Hunan Kangda Detoxification Center and 8 were hospitalised in Brain Hospital of Hunan Province. The other 30 patients were from the in-patient and out-patient of the Second Xiangya Hospital, Central South University.
All the included patients met the following criteria: (a) all the patients were mono-ketamine abusers, or poly drug abusers including ketamine; (b) all the patients had current LUTS but denied it before drug abuse; (c) all the patients had normal renal function confirmed by biochemical test; (d) these patients denied any therapy prior to hospitalisation; and (e) exclusion of other diseases that were associated LUTS, like urinary tract infections, tuberculosis, urinary stones, tumours, prostatic hyperplasia and prostatitis previously diagnosed or by clinical assessment of history, urine culture, X-rays and/or ultrasound.
All the patients were interviewed by one of our three trained investigators (face-to-face interview method). The interview process did not exceed 45 minutes. The Patients were considered to have storage symptom when the sum of the above three items scored ≥4 and voiding symptoms when the sum of four items scored ≥5.
Survey instrument
11 Lower scores represented the minimal symptom, and higher scores represented severe symptom. IPSS score range from 0-7 meaning minor symptoms, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] indicating moderate symptoms and 20-35 representing severe symptoms.
12
Ethics statement
We obtained the ethical approval for this study from the Institutional Review Board of the Second Xiangya Hospital, Central South University. All the questionnaires were collected and kept by a study administrator. The data drawn from the questionnaires was used for this study only and to be destroyed after the study.
Statistical analysis
The software used for statistical analysis was SPSS for Windows, Version 16.0. Chicago, SPSS Inc. Cronbach's α measuring internal consistency (reliability), Kaiser-Meyer-Olkin (KMO) and Bartlett's test assessing validity were performed. Independent t test was used in two-group comparison. Multiple linear regression analysis was carried out to explore potential predictors of IPSS and QoL. A p value <0.05 was considered as significant difference.
Results
Reliability and validity
Cronbach's α coefficient for reliability and KMO for validity of the instrument were 0.727 and 0.796, respectively. The p value of Bartlett's test was less than 0.01. These results indicated that a good quality of the instrument and the data was suitable for further analysis. 
Demographic characteristics
All the questionnaires from the 100 patients were completed and the return rate was 100% without any missed item. The demographic characteristics of the whole population of patients were listed in Table 2 . Of the 100 patients, 74 (74%) were male and 26 (26%) were female. Their age ranged from 19 to 60 years old, with mean age 28.32±6.46. Ketamine abusers were predominantly young patients as 73 (73%) of them were less than 30 years old. Patients were divided into two subgroups according to living status, living alone and living together with regular partners. The results indicated 60% of them lived alone, while 40% lived together with regular partners. Out of all patients, 36% graduated from junior high schools and below, 64% from senior high schools and above. For the substance abuse pattern, 14% were mono-ketamine abusers, 86% of them were poly-drug abusers including ketamine, methamphetamines, methylene dioxymetham-phetamine (MDMA) and morphine. 
Scores of IPSS and QoL in whole population of patients
IPSS score in the 100 patients ranged from 1 to 30, with mean score 13.02±6.38. In our study, 18 patients presented minor symptoms, 66 had moderate symptoms and 16 suffered from severe symptoms. Eighty-one (81%) of the 100 patients had the sum of storage symptom score ≥4, while 41 (41%) of them having the sum of voiding symptom score ≥5. Score of QoL ranged from 0 to 6, with mean score 3.64± 1.62. 55% of patients had scores more than 3 in QoL. 
Predicting factors of IPSS and QoL
Multiple linear regression analysis was performed to explore independent predictors of IPSS and QoL (Table  4) . Gender, age, living status, educational background, MKA or PDA, duration, frequency and dose of ketamine abuse were entered into the regression model as independent factors. The p values of ANOVA for both two regression model were statistically significant, for IPSS as dependent factor (F=6.504, p<0.001) and QoL (F=4.582, p<0.001), respectively. The results of multiple linear regression analysis both indicated that subjects with lower educational level, mono-ketamine abuse, and longer duration of ketamine abuse were independent predictor of IPSS and QoL. These results indicated that compared with patients with contrast situations, patients with lower educational level, monoketamine abuse and/or longer duration of ketamine abuse, had higher IPSS and lower QoL scores, suffered more severe symptoms from ketamine abuse and had lower quality of life. Gender, age, living status, current abusing frequency and dose of ketamine cannot demonstrate statistically significant difference. 
Discussion
Ketamine is widely used as an anesthetic and analgesic in pain management, paediatrics and veterinary anaesthesia. 13 Its non-medical use is firstly reported in 1960s.
14 In recent decades, ketamine is abused as a newtype abusive-drug all over the world through snorting, inhaling and ingestion.
14 Ketamine-induced uropathy (KIU) gets focused since 2007.
1,2 Its toxicity involves not only urinar y tract, but also reproductive function. 3, 15, 16 Multiple acute or chronic physical and psychological effects were also reported. 13 A large series demonstrated that ketamine abusers were commonly poly-drug users. 8 The effects of mono-ketamine use and poly-drug use to LUTS and QoL, remains unknown and need further exploration. LUTS are typical and salient symptoms of KIU; however, issues including assessing LUTS are unsolved. 3 Thus the main aim of this study was firstly to specifically evaluate LUTS and QoL in ketamine abusers and to find out if there is any difference between mono-ketamine use and poly-drug use in ketamine-induced LUTS.
IPSS has been a questionnaire for evaluating the symptom severity of benign prostatic hyperplasia in male patients 12 and has also been available to survey female patients with LUTS. [17] [18] [19] As mentioned above that LUTS are typical and salient symptoms of KIU, instruments of IPSS and QoL is thus used to assess the LUTS induced by KIU. In our study, 100 patients were assessed but out of these 74% were male and 26% were female with mean age of about 28 years old, respectively. Similar to the previous study, 8 ketamine abusers were mostly young people. In our study, 86% of them were reported to be poly-drug users; in contrast 14% were mono-ketamine users. These percentages were lower than the reports of Winstock et al, 8 probably due to the geographic and racial differences. The overall prevalence of LUTS in the patient population indicated that 82(82%) of them suffers moderate and severe urinary tract symptoms respectively. For these patients, medical intervention might be needed for implications of improving their sufferings. Meanwhile 55% of all patients scored more than 3 in QoL, indicated that their quality of lives were obviously affected by the LUTS. The results showed 81% patients have storage symptoms compared to 41% with voiding symptoms, indicating that among the whole ketamine abusers, storage symptoms were more affected, which might be due to thicken fibrotic bladder wall and decreased bladder volume induced by ketamine abuse. 3, 4 The results from further comparisons, suggested that no significant differences were found in gender, age, and living status in IPSS and QoL, indicating that patients among these groups have similar effects and experiences in ketamine-induced LUTS and QoL. This illustrated that ketamine induced urinary symptoms were not dependent on age and gender.
It was demonstrated that mono-ketamine abusers experienced higher level LUTS and lived lower quality of life than poly-drug users who suffered more symptoms of storage and voiding functions. This is likely related to the cumulative dose of abused ketamine as poly-drug abusers commonly had lower abusive dose of ketamine, while the adverse effects of other abusive drugs were not demonstrated. This also illustrate that ketamine was the sole abusive drug that induced uropathy and LUTS, as described in published articles. 2, 8 With the multiple regression analysis, compared with poly-drug abuse, IPSS and QoL scores were found predicted by the duration of ketamine abuse, while the frequency and dose of ketamine abuse were not affecting factors on both of them, which seemed not to meet the findings of previous reports. [2] [3] [4] [5] 8 Duration of abuse was closely associated with the cumulative ketamine abusive dose which would be had the key association with LUTS. In previous studies, [2] [3] [4] [5] 8 the frequency and dose of ketamine abuse were both supposed to affect severity of symptoms in ketamine abusers. In our study, the definition of frequency and dose were based on the current abusive dose, which may not truly reflect the cumulative dose in fact. In addition, we found that educational background was a protective factor and negatively correlated with LUTS in ketamine abusers, which might be due to patients with school failure might tend to indulge themselves. 20 
Limitations
Our study included subjects attended detoxication centre or hospitalised, there is intrinsic selection bias. There may be variations in skills and tones on questioning between the three interviewers during the face-to-face interview. IPSS was not well validated for assessment of ketamine-associated urinary symptoms, and symptoms such as hematuria were not evaluated with IPSS. The scale of QoL is not a well validated score and method.
Conclusions
About 82 (82%) of ketamine abusers report moderateto-severe LUTS. Lower educations level, mono-ketamine abuse and longer duration of abuse are predictors of LUTS and quality of life in ketamine abusers.
